![Sylvain Chemtob](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Sylvain Chemtob
Corporate Officer/Principal presso University of Montréal
Relazioni attive
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Bert Vandal | M | 63 |
McGill University
| 18 anni |
Tullio Cedraschi | M | 85 |
McGill University
| - |
John Edward Cleghorn | M | 82 |
McGill University
| - |
David S. Morse | M | 67 |
University of Montréal
| 23 anni |
Hugh Scott | M | - |
McGill University
| - |
Mikihiro Yasuda | M | 53 |
McGill University
| 11 anni |
Nicola Walter Palmieri | M | 89 |
McGill University
| - |
Marcel Messier | M | - |
University of Montréal
| - |
David Goltzman | M | - |
McGill University
| - |
Armen Aprikian | M | - |
McGill University
| - |
Marc-André Aubé | M | 52 |
University of Montréal
| - |
Ann Letellier | M | - |
University of Montréal
| - |
Paul Chipperton | M | - |
McGill University
| - |
Hyman M. Schipper | M | - |
McGill University
| - |
Marie-Josée Lamothe | F | 56 |
McGill University
| - |
Johanne Tremblay | M | - |
University of Montréal
| - |
Joel Cohen | M | - |
McGill University
| - |
Warren J. Gross | M | - |
McGill University
| - |
Shie Mannor | M | - |
McGill University
| - |
Peter D. Nesgos | M | - |
McGill University
| - |
Murray P. Ducharme | M | - |
University of Montréal
| - |
Stephen W. Michnick | M | - |
University of Montréal
| - |
Pierre Matuszewski | M | - |
McGill University
| - |
Joe Clark | M | - |
McGill University
| - |
Guy Laliberté | M | - |
McGill University
| - |
Michael Churchill-smith | M | - |
McGill University
| 37 anni |
Mark Ware | M | - |
McGill University
| 23 anni |
Daniel Levitin | M | - |
McGill University
| - |
Alvin Shrier | M | - |
McGill University
| - |
Tina Hobday | F | - |
McGill University
| - |
Danny Ritter | M | - |
McGill University
| - |
Michael DiGrappa | M | - |
McGill University
| - |
Sarkis Meterissian | M | 62 |
McGill University
| - |
Moutih Rafei | M | 42 |
University of Montréal
| - |
Jean-Francois Yale | M | - |
McGill University
| - |
Luc Villeneuve | M | - |
University of Montréal
| 9 anni |
Juan Carlos Calderón Rojas | M | - |
University of Montréal
| - |
Melissa Sonberg | F | 64 |
McGill University
| 10 anni |
Amit Bar-Or | M | - |
McGill University
| - |
Viviane Yargeau | M | - |
McGill University
| 20 anni |
Jeannie L. Haggerty | M | - |
McGill University
| - |
Richard Morisset | M | - |
University of Montréal
| - |
Elliot Lifson | M | - |
McGill University
| - |
Hartley S. Stern | M | - |
McGill University
| - |
Robert Lacroix | M | 84 |
University of Montréal
| 54 anni |
Nicolas Matziorinis | M | - |
McGill University
| 36 anni |
John W. Commissiong | M | 79 |
McGill University
| - |
Jean-Marc Léger | M | 62 |
University of Montréal
| - |
Lawrence Hoffman | M | - |
McGill University
| - |
Samira Sakhia | F | 55 |
McGill University
| - |
Stephen Halperin | M | 74 |
McGill University
| - |
Monique Leroux | F | 69 |
University of Montréal
| 9 anni |
Françoise Guénette | F | - |
University of Montréal
| - |
Hans J. Mäder | M | - |
University of Montréal
| - |
James Jonathan Nelson | M | 76 |
McGill University
| - |
Pavel Hamet | M | - |
University of Montréal
| - |
Robert Dutton | M | 69 |
University of Montréal
| - |
Lucien Bouchard | M | 86 |
University of Montréal
| - |
Maryse Bertrand | F | 65 |
McGill University
| 8 anni |
Manon R. Vennat | F | - |
McGill University
| - |
Maurice St. Jacques | M | - |
University of Montréal
| - |
Gerald Sheff | M | - |
McGill University
| - |
Rémi Marcoux | M | 83 |
University of Montréal
| 20 anni |
Marcel Dutil | M | 81 |
University of Montréal
| - |
Thomas Kierans | M | 81 |
McGill University
| - |
Jacques Gauthier | M | 62 |
University of Montréal
| - |
François Painchaud | M | 60 |
McGill University
| - |
Richard I. Levin | M | 75 |
McGill University
| 18 anni |
Samuel Minzberg | M | 67 |
McGill University
| - |
Jan Peeters | M | 72 |
McGill University
| 25 anni |
Michael Boychuk | M | 68 |
McGill University
| - |
Perry Miele | M | 64 |
McGill University
| - |
Ronald D. Guttmann | M | 87 |
McGill University
| - |
Gordon C. Shore | M | - |
McGill University
| - |
Phillip Gold | M | 83 |
McGill University
| - |
Xin Zhao | M | 63 |
McGill University
| 31 anni |
C. Joseph Clark | M | - |
McGill University
| - |
Lise Fournel | F | - |
University of Montréal
| - |
Francine Gervais | M | - |
McGill University
| - |
Siegfried Hekimi | M | - |
McGill University
| - |
Nathalie Bourque | F | - |
McGill University
| - |
Robert G. Goyer | M | - |
University of Montréal
| - |
Robert Panet-Raymond | M | 81 |
University of Montréal
| - |
François Gilbert | M | - |
McGill University
| - |
Kenneth S. Atlas | M | - |
McGill University
| - |
Allan Pont | M | - |
McGill University
| - |
François Martin | M | - |
University of Montréal
| - |
Patrick Colin | M | - |
University of Montréal
| - |
Louis Vachon | M | 61 |
University of Montréal
| - |
Martine Turcotte | F | 63 |
McGill University
| - |
Emily Hamilton | M | - |
McGill University
| - |
Paolo Renzi | M | - |
University of Montréal
| - |
Andrew Karaplis | M | - |
McGill University
| - |
Tony Falco | M | - |
McGill University
| - |
Giovanna Santullo | F | - |
McGill University
| - |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Mark E. Kaufmann | M | 56 |
Allostera Pharma, Inc.
![]() Allostera Pharma, Inc. Medical DistributorsDistribution Services Allostera Pharma Inc. is a biopharmaceutical company that has developed an entirely new class of drugs, called Allosteramers™. Allosteramers™ have three main properties: 1) they are “allosteric”, meaning they do not bind to the same site as traditional drugs, potentially providing better safety, efficacy and an entirely new set of patentable intellectual properties, 2) they can have predictable and consistent drug properties, and 3) they are designed to be orally available. Using its Module X technology platform, Allostera has developed a pipeline of seven novel Allosteramers™ against different targets primarily focused on inflammation and autoimmunity including APG2305, a drug inhibiting the IL23 receptor, one of the most important targets in the autoimmune disease field. APG2305 has demonstrated oral activity in animal models of autoimmune diseases. | 5 anni |
Christiane Quiniou | M | - |
Allostera Pharma, Inc.
![]() Allostera Pharma, Inc. Medical DistributorsDistribution Services Allostera Pharma Inc. is a biopharmaceutical company that has developed an entirely new class of drugs, called Allosteramers™. Allosteramers™ have three main properties: 1) they are “allosteric”, meaning they do not bind to the same site as traditional drugs, potentially providing better safety, efficacy and an entirely new set of patentable intellectual properties, 2) they can have predictable and consistent drug properties, and 3) they are designed to be orally available. Using its Module X technology platform, Allostera has developed a pipeline of seven novel Allosteramers™ against different targets primarily focused on inflammation and autoimmunity including APG2305, a drug inhibiting the IL23 receptor, one of the most important targets in the autoimmune disease field. APG2305 has demonstrated oral activity in animal models of autoimmune diseases. | 8 anni |
Bogdan Dziurzynski | M | 75 |
Allostera Pharma, Inc.
![]() Allostera Pharma, Inc. Medical DistributorsDistribution Services Allostera Pharma Inc. is a biopharmaceutical company that has developed an entirely new class of drugs, called Allosteramers™. Allosteramers™ have three main properties: 1) they are “allosteric”, meaning they do not bind to the same site as traditional drugs, potentially providing better safety, efficacy and an entirely new set of patentable intellectual properties, 2) they can have predictable and consistent drug properties, and 3) they are designed to be orally available. Using its Module X technology platform, Allostera has developed a pipeline of seven novel Allosteramers™ against different targets primarily focused on inflammation and autoimmunity including APG2305, a drug inhibiting the IL23 receptor, one of the most important targets in the autoimmune disease field. APG2305 has demonstrated oral activity in animal models of autoimmune diseases. | - |
Christopher Henney | M | 83 |
Allostera Pharma, Inc.
![]() Allostera Pharma, Inc. Medical DistributorsDistribution Services Allostera Pharma Inc. is a biopharmaceutical company that has developed an entirely new class of drugs, called Allosteramers™. Allosteramers™ have three main properties: 1) they are “allosteric”, meaning they do not bind to the same site as traditional drugs, potentially providing better safety, efficacy and an entirely new set of patentable intellectual properties, 2) they can have predictable and consistent drug properties, and 3) they are designed to be orally available. Using its Module X technology platform, Allostera has developed a pipeline of seven novel Allosteramers™ against different targets primarily focused on inflammation and autoimmunity including APG2305, a drug inhibiting the IL23 receptor, one of the most important targets in the autoimmune disease field. APG2305 has demonstrated oral activity in animal models of autoimmune diseases. | 3 anni |
Shawn Barney | M | - |
Allostera Pharma, Inc.
![]() Allostera Pharma, Inc. Medical DistributorsDistribution Services Allostera Pharma Inc. is a biopharmaceutical company that has developed an entirely new class of drugs, called Allosteramers™. Allosteramers™ have three main properties: 1) they are “allosteric”, meaning they do not bind to the same site as traditional drugs, potentially providing better safety, efficacy and an entirely new set of patentable intellectual properties, 2) they can have predictable and consistent drug properties, and 3) they are designed to be orally available. Using its Module X technology platform, Allostera has developed a pipeline of seven novel Allosteramers™ against different targets primarily focused on inflammation and autoimmunity including APG2305, a drug inhibiting the IL23 receptor, one of the most important targets in the autoimmune disease field. APG2305 has demonstrated oral activity in animal models of autoimmune diseases. | - |
Statistiche
Paese | Relazioni | % del totale |
---|---|---|
Canada | 100 | 100.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Sylvain Chemtob
- Contatti personali